This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Biotech ETFs Soars on Gilead-Immunomedics Deal
by Sweta Killa
The acquisition will expand Gilead's portfolio of treatments for various types of cancer.
5 ETFs Jump After Three-Day Rout: Will The Rally Last?
by Sweta Killa
We have highlighted ETFs that were at the forefront of the market rebound on Sep 9 and will continue to do so if market sentiments remain positive.
Will Novavax ETFs Gain on Coronavirus Vaccine Progress?
by Sweta Jaiswal, FRM
Investors are closely tracking the progress in the coronavirus vaccine development amid the coronavirus outbreak.
ETF Winners & Losers From Wall Street's Worst Day Since June
by Sweta Killa
After a massive rally, Wall Street suffered its worst day in almost three months as investors' dumped the high-flying technology stocks.
ETFs Set to Surge on Virtual Healthcare Deal
by Sweta Killa
The ongoing boom in online care and consultations has led to merger & acquisition activity in the telehealth services space.
COVID-19 Vaccine Push Brings Hope: Stock & ETF Beneficiaries
by Sanghamitra Saha
There are at least a hundred candidates in the COVID-19 vaccine race globally. However, few companies like Moderna, Pfizer and AstraZeneca are showing considerable hope.
Markets Brave Coronavirus Second Wave: 5 Best ETFs of Last Week
by Sanghamitra Saha
Last week was moderate for the Wall Street despite rising coronavirus cases.
Stocks & ETFs Beneficiaries of Coronavirus Vaccine Ramp-Up
by Sanghamitra Saha
Efforts in formulating a coronavirus vaccine are heating up. These stocks and ETFs look to be the largest beneficiaries.
Wining ETF Areas of Last Week
by Sanghamitra Saha
Though last week was not upbeat for Wall Street, these ETFs breezed past Wall Street.
Novavax Soars on Coronavirus Vaccine Funding: ETFs to Gain
by Sweta Jaiswal, FRM
Novavax received funding for the coronavirus vaccine and also delivered better-than-expected Q1 results resulting in a stock rally in yesterday's trading session.